Investigation of a Prostate Cancer Radiation Response Signature in the Breast Cancer SweBCG91RT Randomized Trial.
Shuang G Zhao, Erik Holmberg, Dan Lundstedt et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the Prostate cancer Radiation Therapy Outcomes Score (PORTOS) in predicting radiotherapy benefit in 765 patients with early-stage breast cancer. The study found a significant interaction (P = 0.049) between PORTOS scores and the 10-year cumulative incidence of any recurrence, indicating that patients in the top 75% of PORTOS scores had a subdistribution hazard ratio of 0.46 (P < 0.001) for recurrence compared to those in the bottom 25%.
Key findings
- Patients in the top 75% of PORTOS scores had a 10-year cumulative incidence of recurrence with SHR = 0.46 (P < 0.001).
- A significant interaction (P = 0.049) was found between PORTOS scores and radiotherapy benefit.
- Higher PORTOS scores were associated with increased risk of RT-related breast pain, with an interaction P value of 0.07.
Why it matters
The findings suggest that PORTOS can serve as a predictive biomarker for radiotherapy benefit in breast cancer, potentially guiding treatment decisions and improving patient outcomes by identifying those who may benefit most from radiation therapy.